FBIO
TGTX
MBIO

Michael S. Weiss

Known title: CEO and PresidentCIK: 0001038977

Michael S. Weiss's purchase track record

How the stock did after each of Michael S. Weiss's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.

Purchases measured
3
of 3 since February 10, 2023
Stock higher 6 months later
67%
3 months: 67%
Median 6-month return
+33.3%
3 months: +0.9%
Beat the S&P 500
67%
median +16.6% vs. index
PurchaseStockAmount3 months6 months
11/14/2023FBIO$250K+34.1%+33.3%
8/11/2023TGTX$1.01M+0.9%+45.5%
2/10/2023FBIO$1000K-5.3%-30.3%

Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.

Associated companies

this person other insiders at FBIO

AI Market Commentary

AI-generatedAll commentary →

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

October 7, 2026

TGTX Highlighted as Affordable Biotech Growth Play. ChartMill recently featured TG Therapeutics as an affordable growth option within the biotech sector. This analysis suggests the stock may be viewed as undervalued relative to its potential, despite trading near its 52-week low. The mention adds a positive fundamental perspective to the current technical setup.

this person other insiders at TGTX
this person other insiders at MBIO

Transaction History

FBIO▲ Buy$0
TGTX▲ Buy$0
TGTX▼ Sell$0
TGTX▼ Sell$0
TGTX▲ Buy$0
FBIO▲ Buy$0
TGTX▲ Buy$0
FBIO▲ Buy$0
FBIO▲ Buy$250K
TGTX▲ Buy$1.0M
MBIO▲ Buy$0
TGTX▲ Buy$0
FBIO▲ Buy$1000K
FBIO▲ Buy$0
MBIO▲ Buy$0
TGTX▼ Sell$562K
TGTX▼ Sell$721K
FBIO▲ Buy$0
TGTX▲ Buy$0
TGTX▼ Sell$0
TGTX▼ Sell$0
TGTX▼ Sell$0

We use analytics to understand how market-wall is used. No personal data is sold.